
    
      This was a prospective randomized double-blinded study, in which patients were recruited from
      august 2013 until august 2014. Outpatients attended in 4 otolaryngology clinics from
      Crici√∫ma, state of Santa Catarina, Brazil were invited to participate of the study. They were
      aged between 18 and 63 years. Seventy-three patient were included, of whom 36 were treated
      with loratadine 10 mg and 37 with bilastine 20 mg with medication administered once a day for
      ten days. The primary outcome was quality of life, assessed by the modified
      Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm), which was applied at baseline and
      after 10 days of treatment.
    
  